Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug
Authors:
- P RaananiPRP Raanani
- I HardanIHI Hardan
- A AvigdorAAA Avigdor
- I LeviILI Levi
- M BerkowiczMBM Berkowicz
- Ben‐ BassatBBBen‐ Bassat
- 1 February 2000
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 108 (2) , 391-393
Abstract
We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200–800 mg/day. Eleven patients responded, five of whom had a very good partial response (> 75% decline in M protein) and another five exhibited a partial response (> 50% decline in M protein). Except for one patient, treatment was well tolerated with only mild side‐effects. Thalidomide should be included in the therapeutic options for refractory myeloma.Keywords
This publication has 5 references indexed in Scilit:
- Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple MyelomaBlood, 1999
- Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple MyelomaBlood, 1999
- Clinical Applications of Research on AngiogenesisNew England Journal of Medicine, 1995
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994